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Abstract
We report the ﬁrst case of peritonitis attributed to Mycobacte-
rium heckeshornense. This is a rare, non-tuberculous mycobacte-
rium that has been reported as an aetiological agent in a
growing number and widening spectrum of infections.
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Case report
We present the case of a 76-year-old male with end-stage
renal disease on peritoneal dialysis (PD). He previously failed
a renal transplant, and was no longer on immunosuppressive
medications. In March 2010, he presented with increasing
cough, dyspnoea, and orthopnoea. Radiological ﬁndings were
consistent with pulmonary oedema, and he was diagnosed
with volume overload and admitted. Despite the concentra-
tion of the PD ﬂuid being increased to 4.25% and the institu-
tion of volume restriction, his respiratory function continued
to deteriorate. He was transferred to the intensive-care unit
for bilevel positive airway pressure (BiPAP), but this failed,
and he required intubation for respiratory failure. Concur-
rently, the patient developed abdominal pain with voluntary
guarding and left-sided tenderness, fever, and profound hypo-
tension requiring vasopressor support. Abdominal ultrasound
and computed tomography scan were non-contributory.
With a diagnosis of septic shock secondary to peritonitis,
empirical antibiotics were started (vancomycin and piperacil-
lin–tazobactam intravenously; vancomycin and tobramycin
intraperitoneally) and a concomitant diagnostic sample of
peritoneal ﬂuid was obtained.
The ﬂuid white blood cell count was 545 cells/mm3 (43%
neutrophils). No organisms were seen on the Gram, fungal
or acid-fast bacilli stains (auramine O); cultures were set up
for bacteria, fungi, and mycobacteria. Bacterial cultures were
negative after 7 days of incubation; fungal and mycobacterial
cultures were likewise negative throughout the ﬁrst 14 days.
The antibiotics were continued for 2 weeks. The patient
improved enough to leave the intensive-care unit, despite
repeated bouts of hypotension. At that point, PD was
thought to be no longer viable because of ongoing peritoni-
tis, and he was switched to haemodialysis. The remaining 2 L
of his peritoneal ﬂuid was drained, and the PD catheter was
removed. A sample of this terminal drainage revealed a white
blood cell count of 1595 cells/mm3. Because the original cul-
tures were still negative at this time, no mycobacterial cul-
tures from this latter specimen or the catheter itself were
ordered.
However, after 20 days of incubation, the mycobacterial
cultures from the original specimen ﬂagged positive on the
BACTEC MGIT 960 system (BD, Sparks, MD, USA). Testing
for Mycobacterium tuberculosis complex and Mycobacterium
avium complex, with AccuProbe assays (Gen-Probe, San
Diego, CA, USA), gave negative results. The organism was
submitted to the provincial reference laboratory at the
British Columbia Centre for Disease Control for deﬁnitive
identiﬁcation. Slowly growing, smooth, yellow-pigmented
colonies were observed on Lowenstein–Jensen agar. A near
full-length fragment of the 16S rRNA gene (1424 bp) and a
401-bp fragment of the hsp65 gene were sequenced as previ-
ously described [1]. The 16S rRNA gene had 100% sequence
identity with both Mycobacterium heckeshornense and Myco-
bacterium xenopi sequences in NCBI, but hsp65 had 99.5%
sequence identity with M. heckeshornense and 97.5% with
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M. xenopi. Thus, the organism was determined to be
M. heckeshornense.
The patient’s peritonitis and hypotension resolved after
catheter removal and peritoneal ﬂuid drainage, which was
thought to constitute adequate source control. His clinical
picture improved, and no antimycobacterial agents were
therefore administered. The patient continues to be well at
the present time.
Discussion
M. heckeshornense was ﬁrst described in 2000 [2], and is
named after the Berlin suburb containing the clinic where it
was ﬁrst treated. Phylogenetically, it is most closely related
to M. xenopi. Whereas the latter is well documented as being
ubiquitous, with a particular predilection for water [3],
M. heckeshornense has not been reported in similar environ-
mental contexts. Although it has been isolated from porcine
lymph nodes [4], most occurrences have been in human
clinical specimens (Table 1).
The ﬁrst isolation of M. heckeshornense was in a case of
relapsing cavitary pulmonary disease [2]. Since then, there
have been multiple reports of M. heckeshornense as a pulmo-
nary pathogen [5–8]. Patients exhibit disease similar to
tuberculosis, with cavitary lesions, respiratory complaints of
cough and dyspnoea, and systemic symptoms of weight loss
and fatigue. Extrapulmonary disease has been described,
including lymphadenitis [9], tenosynovitis [10], lumbar
spondylodiscitis [11], and disseminated infection with bacter-
aemia in a patient with severe human immunodeﬁciency
virus infection [12].
M. heckeshornense stains acid-fast. Like M. xenopi, it is a
slow-growing scotochromagen, growing in temperatures
from 37C to 45C. Its biochemical proﬁle is largely inert; it
tests positive only for heat-stable catalase. Notably, it differs
from M. xenopi with regard to negative results for arylsulfa-
tase, nicotinimidase, and pyrazinimidase [2]. Proﬁles for vari-
ous modalities of molecular characterization have been
described, including mycolic acid analysis [2], cellular fatty
acid analysis [2,13], and rapid fragment length polymorphism
testing of hsp65 [14]. DNA sequencing is increasingly being
used. Targets include the 16S rRNA gene, rpoB [15], and
hsp65 [1,9,10]. DNA–DNA hybridization [6] has also been
employed.
Susceptibility testing has been reported infrequently. The
modiﬁed agar proportion [2] and the BACTEC 460 radio-
metric broth (BD) methods [10,12] have been used, as well
as an unspeciﬁed method in another study [7].One study
reported MIC values [12]. The organism was reported as
being non-susceptible to isoniazid in three cases, and one
isolate was reported to be resistant to rifampin [2]. No in vi-
tro resistance to ciproﬂoxacin, clarithromycin or streptomy-
cin has been reported.
Because of its rarity, there is a lack of clinical experience
with treatment of M. heckeshornense infections; obviously, no
therapeutic guidelines exist. Anecdotally, prolonged courses
of combination antibiotic therapy have been tried [2,7,11].
Regimens have included antituberculosis medications (isonia-
zid, rifampin, ethambutol, and pyrazinimide), and clarithromy-
cin and quinolones have also been common choices.
Removal of an infective nidus, where possible, plays an
important role in therapy. In cases of tenosynovitis [10]
and lymphadenitis [9], disease resolved without the use of
TABLE 1. Summary of Mycobacterium heckeshornense cases in the English literature
Patient Clinical presentation Target of identiﬁcation Susceptibilities Treatment Outcome
Year and
reference
30F Pulmonary: recurrent
bilateral cavitary disease
Sequence (16S rRNA,
16S–23S spacer)
R: INH, RIF
S: ETH, STR, CIP, CLM
INH, RIF, ETH,
protionamide
Failed, only clearing
after surgical resection
2000 [2]
43M Pulmonary: pneumothorac-
es with systemic symp-
toms
Sequence (16S rRNA) ND INH, PYR, RIF, ETH Resolved 2004 [7]
73M Pulmonary: right upper
lobe cavitary disease
Sequence (16S rRNA) R: AMI
I: INH, ETH
S: RIF, STR, CIP, CLM
INH, RIF, CLM, LEV Not discussed 2004 [7]
86F Tenosynovitis Sequence (16S rRNA, hsp65) R: INH
S: RIF, ETH, STR
Surgical resection Resolved 2006 [10]
65F Pulmonary Reverse hybridization line probe ND CLM, ETH, MOX Resolved 2007 [5]
51M Lumbar spondylodiscitis Sequence (16S rRNA) ND CLM, RIF, MOX,
surgical debridement
84F Lymphadenitis Sequence (16S rRNA, hsp65) ND Surgical resection Resolved 2009 [9]
40M Disseminated with
bacteraemia
Sequence (16S rRNA) MICs: INH, 1; RFB, £0.12;
ETH, £8; STR, 8; CIP,
£2; CLM, £16; AMI, £2
INH, RFB, CLM, MOX Resolved 2010 [12]
R, resistant; I, intermediate; S, susceptible; ND, not described; INH, isoniazid, RIF, rifampin; ETH, ethambutol; STR, streptomycin; CIP, ciproﬂoxacin; CLM, clarithromycin;
AMI, amikacin; RFB, rifabutin; PYR, pyrazinimide; LEV, levoﬂoxacin; MOX, moxiﬂoxacin. All MICs are in mg/L.
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chemotherapeutic agents. Furthermore, in the original case
description [2], the disease relapsed, despite a 12-month
course of antimicrobials. It was not until after bilateral upper
lung lobectomies and additional chemotherapy that cure was
achieved.
We describe the ﬁrst case of peritoneal infection with
M. heckeshornense, in the setting of a patient with end-stage
renal disease on PD. The peritonitis resolved without the
use of speciﬁc antimicrobial medications, and this can proba-
bly be attributed to the source control involving peritoneal
catheter removal and ﬂuid drainage. Adequate source control
alone has been found to be sufﬁcient to clear M. heckeshorn-
ense infections in multiple reports, and our case of M. hecke-
shornense peritonitis is consistent with these ﬁndings.
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Abstract
In clinical studies on bacteraemia, the negativity of blood cul-
tures is an important endpoint for comparing the efﬁcacy of dif-
ferent therapeutic regimens. In FAN anaerobic blood culture
medium (BacT/ALERT system), daptomycin displayed increased
MIC against Staphylococcus aureus and improved abolishment of
its carryover effect in charcoal when compared with vancomy-
cin. Differences between these two drugs can lead to a false
interpretation of negative blood cultures. To compare different
antibiotic regimens for the treatment of bacteraemia, preliminary
studies are mandatory to ensure that ex vivo antibiotic behaviour
is similar in the blood-culture system used.
Keywords: Bacteraemia, blood cultures, daptomycin,
Staphylococcus aureus, vancomycin
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